Modality
Gene Therapy
MOA
MDM2i
Target
PD-L1
Pathway
Innate Imm
HSNBCholangiocarcinoma
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
Nov 2017
→ Sep 2029
Phase 2Current
NCT04275171
1,889 pts·Cholangiocarcinoma
2017-11→2029-09·Not yet recruiting
NCT03052220
1,756 pts·HS
2019-10→2025-02·Completed
3,645 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-121.1y agoPh2 Data· HS
2029-09-133.5y awayPh2 Data· Cholangiocarcinoma
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2025-02-12 · 1.1y ago
HS
Ph2 Data
2029-09-13 · 3.5y away
Cholangiocarcinoma
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04275171 | Phase 2 | Cholangiocarcinoma | Not yet recr... | 1889 | OS |
| NCT03052220 | Phase 2 | HS | Completed | 1756 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |